Corcept Therapeutics Incorporated
CORT
$33.60
$0.300.90%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 23.49% | -44.04% | 71.07% | -33.17% | -34.88% |
| Total Depreciation and Amortization | 1.05% | 1.71% | 1.52% | 0.43% | -7.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -85.50% | 58,567.92% | -100.82% | -40.15% | 645.26% |
| Change in Net Operating Assets | 174.34% | -60.02% | 137.53% | -223.24% | -34.29% |
| Cash from Operations | -29.43% | 23.99% | 756.84% | -91.46% | -18.06% |
| Capital Expenditure | -- | 100.00% | 45.19% | 14.05% | 92.60% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -180.53% | -79.13% | 2,388.36% | 95.23% | -51.50% |
| Cash from Investing | -180.87% | -79.12% | 2,311.51% | 95.07% | -46.15% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 26.62% | -66.40% | 262.08% | 42.71% | 6.70% |
| Repurchase of Common Stock | 27.81% | 56.16% | -166.87% | -519.30% | 70.10% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 32.74% | 54.91% | -158.61% | -772.11% | 78.36% |
| Foreign Exchange rate Adjustments | 90.00% | -117.84% | -- | -- | -241.42% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -120.73% | 73.24% | 134.15% | -293.25% | -210.61% |